Premier Alternatives

Castle Creek Biosciences

Exton, PA · Founded 2015 · Privately Held (backing)

Developer of a fibroblast based therepy designed to treat rare and serious genetic diseases. Castle Creek Biosciences is based in Exton, PA and was founded in 2015. It has raised $419 million across 4 recorded rounds; the latest was a $75 million later-stage round in Feb 2025.

PMV mark · valuation
—
Oct 2026
Priced at
—
Total raised
$419.4M
Last round
Later Stage VC
Feb 2025

Castle Creek Biosciences key facts

as of Oct 2026
  • Developer of a fibroblast based therepy designed to treat rare and serious genetic diseases.
  • It has raised $419.4M across 4 recorded rounds; the latest was Later Stage VC ($75.0M) in Feb 2025.
  • Notable investors include Fidelity Management & Research Company, Valor Equity Partners, Fidelity, Paragon Biosciences, U.S. Food and Drug Administration.
  • 2 institutional filers report fund marks on Castle Creek Biosciences across 57 filings.
  • Castle Creek Biosciences has filed 4 Form Ds with the SEC since 2021, most recently Feb 2025 ($75.0M sold to 30 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
—

set by institutional fund marksas of Oct 2026question about this number?
Free account
More of Castle Creek Biosciences with a free account
  • ·Watch Castle Creek Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Institutional fund marks on Castle Creek Biosciences

2 filers · latest Jul 2026

2 SEC-registered funds reported 57 fair-value marks on Castle Creek Biosciences between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.

Unlock 57 fund marks

Membership and data by Private Market View

Every name the funds mark, next to where it trades →

Castle Creek Biosciences funding rounds

4 rounds
Feb 2025Later Stage VC$75.0MSEC filing▮
Apr 2022Later Stage VC$112.8MSEC filing▮
Jan 2022Debt$11.8MSEC filing▮
Jun 2021Debt$25.0MSEC filing▮
Full funding history →

Recent activity

In the last 90 days, Castle Creek Biosciences's record added 7 institutional fund marks (latest period Jul 2026).

How much has Castle Creek Biosciences raised?

Castle Creek Biosciences has raised $419 million across 4 recorded rounds since 2021. The largest was a $75 million later-stage round in Feb 2025.

Castle Creek Biosciences has filed 4 Form Ds with the SEC since 2021, most recently in Feb 2025 ($75 million sold to 30 investors).

Institutional holders and vehicles

2 SEC-registered funds reported 57 fair-value marks on Castle Creek Biosciences between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

Castle Creek Biosciences investors

5 investors are on record for Castle Creek Biosciences, including Fidelity Management & Research Company, Valor Equity Partners, Fidelity and Paragon Biosciences. The later-stage round in Feb 2025 drew 30 investors.

About Castle Creek Biosciences

Developer of a fibroblast based therepy designed to treat rare and serious genetic diseases. The company extracts fibroblast cells from a patient's skin to create localized cell and gene therapies that are tailored to individual biology, enabling physicians to offer personalized treatment options for underserved disorders with limited therapeutic alternatives.

Sector
Healthcare
HQ
Exton, PA, United States
Founded
2015
Employees
36
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.